NDC 63323-0090-20: Sodium Chloride 2.5 meq/mL Injection, Solution, Concentrate
This is a package of Sodium Chloride 2.5 meq/mL Injection, Solution, Concentrate from Fresenius Kabi USA, LLC, first listed with the FDA Apr 2021 and currently FDA-listed.
NDC database record
One package, one record: these facts belong to NDC 63323-090-20 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 63323 labeler · 090 product · 20 package
- Package marketed since
- Apr 28, 2021
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC)
- 0363323090043
- FDA record last changed
- Oct 15, 2026
Other active recalls for Sodium Chloride (different manufacturers) — 6 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 001219
- GCN: 02972
- GPI-14 (Medi-Span): 79750010002050
- HICL (First Databank): 000538
- AHFS class code: 40:12.00.00
- RxCUI (RxNorm): 1807578
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Sodium class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
- It depends on the product. IV forms replace fluid and salt, while injection diluents dissolve other drugs. Other forms are used for rinsing, nasal congestion and nasal care, or to...
- Follow the directions on your product. Many are used as often as needed by adults and children 4 and over. Do not share the bottle, because that can spread infection.
- Some people get fever, irritation or infection at the IV site, or too much fluid in the body. Tell your nurse right away if the IV site hurts or looks red.
- What side effects should I expect with IV sodium chloride?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Sodium Chloride — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
| Medicare Part B allowsASP · J7131 | No ASP payment limit on file for J7131 this quarter. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Billing & reimbursement
Where does this data come from?
- CMS ASP NDC-HCPCS crosswalk · refreshed Nov 22, 2026
- DMEPDAC NDC-HCPCS crosswalk
- openFDA NSDE billing units · refreshed Nov 7, 2026
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 63323-0090-20 You're viewing this | 25 VIAL, PLASTIC in 1 TRAY / 20 mL in 1 VIAL, PLASTIC Inner NDC 63323-090-02 · each plastic vial (20 mL) | 2021-04-28 | — | Active |
| 63323-0090-40 63323-090-40 Main listing | 25 VIAL, PLASTIC in 1 TRAY / 40 mL in 1 VIAL, PLASTIC Inner NDC 63323-090-04 · each plastic vial (40 mL) | 2021-04-28 | — | Active |
This pack shows little to no recent Medicaid volume — a different pack size carries most fills. See all packs ↓
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of Sodium Chloride 2.5 meq/mL Injection, Solution, Concentrate?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Sodium Chloride 2.5 meq/mLthis 63323-0090-20 | Fresenius | 25 vials | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Sodium Chloride inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
2 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Fresenius Kabi USA, LLC labeler code 63323
- Cyanocobalamin 1000 ug/mL Injection, Solution NDC 63323-044-01
- Heparin Sodium 5000 [USP'U]/mL Injection, Solution NDC 63323-047-10
- Magnesium Sulfate 500 mg/mL Injection, Solution NDC 63323-064-02
- Sodium Bicarbonate 42 mg/mL Injection, Solution NDC 63323-083-05
- Sodium Chloride 234 mg/mL Injection, Solution NDC 63323-088-61
- Sodium Bicarbonate 84 mg/mL Injection, Solution NDC 63323-089-50
- Sodium Chloride 4 meq/mL Injection, Solution, Concentrate NDC 63323-093-30
- Sodium Chloride 4 meq/mL Injection, Solution, Concentrate NDC 63323-095-61
- Sodium Chloride 4 meq/mL Injection, Solution, Concentrate NDC 63323-099-63
- Doxorubicin Hydrochloride 2 mg/mL Injection, Solution NDC 63323-101-61
- GEMCITABINE 200 mg/5mL Injection, Powder, Lyophilized, For Solution NDC 63323-102-13
- Cisplatin 1 mg/mL Injection, Solution NDC 63323-103-51
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE 14.6% Sodium Chloride Injection, USP Additive Solution is indicated for parenteral restoration of sodium ion in patients with restricted oral intake. Sodium replacement is specifically indicated in patients with hyponatremia or low salt syndrome. 14.6% Sodium Chloride Additive Solution may also be added to compatible carbohydrate solutions such as dextrose in water to provide electrolytes.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION 14.6% Sodium Chloride Injection, USP Additive Solution is administered intravenously only after addition to a larger volume of fluid . The dose, dilution and rate of injection are dependent upon the individual needs of each patient. All or part of the contents of one or more additive containers may be added to an intravenous solution container.
Concentrations of up to 5% sodium chloride have been administered. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS .)
⛔ Contraindications ▾
CONTRAINDICATIONS 14.6% Sodium Chloride Injection, USP Additive Solution is contraindicated in patients with hypernatremia or fluid retention.
⚠️ Warnings ▾
WARNINGS 14.6% Sodium Chloride Injection, USP is hypertonic and must be diluted prior to administration. Inadvertent direct injection or absorption of concentrated sodium chloride solution may give rise to sudden hypernatremia and such complications as cardiovascular shock, central nervous system disorders, extensive hemolysis, cortical necrosis of the kidneys and severe local tissue necrosis (if administered extravascularly). Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.
In patients with diminished renal function, administration of solutions containing sodium may result in sodium retention. The intravenous administration of this solution (after appropriate dilution) can cause fluid and/or solute overload resulting in dilution of other serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Excessive administration of potassium free solutions may result in significant hypokalemia.
WARNING : This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Sodium overload can occur with intravenous infusion of excessive amounts of sodium-containing solutions. (See WARNINGS and PRECAUTIONS .)
🤰 Pregnancy ▾
Pregnancy Animal reproduction studies have not been conducted with sodium chloride. It is also not known whether sodium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium chloride should be given to a pregnant woman only if clearly needed.
🧒 Pediatric Use ▾
Pediatric Use The safety and effectiveness of 14.6% Sodium Chloride Injection, USP Additive Solution have not been established. Its limited use in pediatric patients has been inadequate to fully define proper dosage and limitations for use.
🧓 Geriatric Use ▾
Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
🆘 Overdosage ▾
OVERDOSAGE In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. (See WARNINGS and PRECAUTIONS .)
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Sodium chloride in water dissociates to provide sodium (Na + ) and chloride (Cl - ) ions. These ions are normal constituents of the body fluids (principally extracellular) and are essential for maintaining electrolyte balance. Sodium is the principal cation of extracellular fluid.
It comprises more than 90% of the total cations at its normal plasma concentration of approximately 142 mEq/liter. While the sodium ion can diffuse across cell membranes, intracellular sodium is maintained at a much lower concentration than extracellular sodium through the expenditure of energy by the cell (so called "sodium cation pump"). Loss of intracellular potassium ion is usually accompanied by an increase in intracellular sodium ion.
When serum sodium concentration is low, the secretion of antidiuretic hormone (ADH) by the pituitary is inhibited, thereby preventing water reabsorption by the distal renal tubules. On the other hand, adrenal secretion of aldosterone increases renal tubular reabsorption of sodium in an effort to re-establish normal serum sodium concentration. Chloride (Cl - ) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells.
The distribution and excretion of sodium (Na + ) and chloride (Cl - ) are largely under the control of the kidney which maintains a balance between intake and output.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED 14.6% Sodium Chloride Injection, USP Additive Solution is supplied as the following: Product Code Unit of Sale Strength/Concentration Each 919020 NDC 63323-090-20 Unit of 25 50 mEq/20 mL (2.5 mEq/mL) NDC 63323-090-02 20 mL fill in a 20 mL Single-dose Plastic Fliptop Vial 919040 NDC 63323-090-40 Unit of 25 100 mEq/40 mL (2.5 mEq/mL) NDC 63323-090-04 40 mL fill in a 50 mL Single-dose Plastic Fliptop Vial Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Preservative Free The container closure is not made with natural rubber latex.
📋 Description ▾
DESCRIPTION 14.6% Sodium Chloride Injection, USP Additive Solution is a sterile, nonpyrogenic, concentrated solution for intravenous administration ONLY AFTER DILUTION to replenish electrolytes. The preparations contain either 2.92 or 5.84 g of sodium chloride (50 or 100 mEq each of Na + and Cl - ) in Water for Injection, USP. The solution contains no bacteriostat, antimicrobial agent or added buffer; pH 4.8 (4.5 to 7.0).
May contain hydrochloric acid for pH adjustment. The osmolar concentration is 5 mOsmol/mL (calc.); specific gravity is 1.10. Sodium Chloride, USP is chemically designated NaCl, a white crystalline compound freely soluble in water.
The semi-rigid material used for the plastic vials is fabricated from a specially formulated polyolefin. It is a copolymer of propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers.
The container requires no vapor barrier to maintain the proper drug concentration.
⚠️ Precautions ▾
PRECAUTIONS 14.6% Sodium Chloride Injection, USP Additive Solution must be diluted before infusion to avoid a sudden increase in the level of plasma sodium. Too rapid administration should be avoided. Special caution should be used in administering sodium containing solutions to patients with severe renal impairment, cirrhosis of the liver, cardiac failure, or other edematous or sodium-retaining states.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin. Do not use unless the solution is clear and seal is intact.
Discard unused portion. Pregnancy Animal reproduction studies have not been conducted with sodium chloride. It is also not known whether sodium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
Sodium chloride should be given to a pregnant woman only if clearly needed. Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Pediatric Use The safety and effectiveness of 14.6% Sodium Chloride Injection, USP Additive Solution have not been established.
Its limited use in pediatric patients has been inadequate to fully define proper dosage and limitations for use.
📄 Package Label / Principal Display Panel ▾
PACKAGE LABEL - PRINCIPAL DISPLAY – 14.6% Sodium Chloride Injection, USP Vial Label NDC 63323-090-02 919020 Rx only 14.6% Sodium Chloride Injection, USP 50 mEq/20 mL (2.5 mEq/mL) CONCENTRATE CAUTION: MUST BE DILUTED FOR I.V. USE 20 mL Single Dose Vial PACKAGE LABEL - PRINCIPAL DISPLAY – 14.6% Sodium Chloride Injection, USP Vial Label
PACKAGE LABEL - PRINCIPAL DISPLAY – 14.6% Sodium Chloride Injection, USP Tray Label NDC 63323-090-20 919020 14.6% Sodium Chloride Injection, USP 50 mEq/20 mL (2.5 mEq/mL) CONCENTRATE CAUTION: MUST BE DILUTED FOR I.V. USE Rx only 25 x 20 mL Single Dose Vials PACKAGE LABEL - PRINCIPAL DISPLAY – 14.6% Sodium Chloride Injection, USP Tray Label
PACKAGE LABEL - PRINCIPAL DISPLAY – 14.6% Sodium Chloride Injection, USP Vial Label NDC 63323-090-04 919040 14.6% Sodium Chloride Injection, USP 100 mEq/40 mL (2.5 mEq/mL) CONCENTRATE CAUTION: MUST BE DILUTED FOR I.V. USE Rx only 40 mL Single Dose Vial PACKAGE LABEL - PRINCIPAL DISPLAY – 14.6% Sodium Chloride Injection, USP Vial Label
PACKAGE LABEL - PRINCIPAL DISPLAY – 14.6% Sodium Chloride Injection, USP Tray Label NDC 63323-090-40 919040 14.6% Sodium Chloride Injection, USP 100 mEq/40 mL (2.5 mEq/mL) CONCENTRATE CAUTION: MUST BE DILUTED FOR I.V. USE Rx only 25 x 40 mL Single Dose Vials PACKAGE LABEL - PRINCIPAL DISPLAY – 14.6% Sodium Chloride Injection, USP Tray Label
Medicaid utilization by pack size
Medicare Part D spend CMS · PART D · 2026 (Q1)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | ✓ Available |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |